January 18, 2012, 9:09 AM EST
By Margaret Cronin Fisk, Jef Feeley and David Voreacos
Jan. 6 (Bloomberg) -- Johnson & Johnson will pay more than
$1 billion to the U.S. and most states to resolve a civil investigation
into marketing of the antipsychotic Risperdal, according to people
familiar with the matter.
J&J, the world’s largest health products
company, reached an agreement last week with the U.S. attorney in
Philadelphia, according to the people, who weren’t authorized to speak
about the matter. Negotiations over a possible criminal plea are still
under way, they said.
The U.S. government has been investigating
Risperdal sales practices since 2004, including allegations the company
marketed the drug for unapproved uses, J&J has said in Securities
and Exchange Commission filings. The company said it has been in
negotiations with the U.S. to settle the investigation.
READ MORE
No comments:
Post a Comment